Navigation Links
Genaera Corporation Presents Data on Mechanism of Inhibition of PTP-1B for Trodusquemine (MSI-1436) at Federation of American Societies for Experimental Biology (FASEB) Meeting
Date:7/14/2008

PLYMOUTH MEETING, Pa., July 14 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) announced today the presentation of new preclinical data on trodusquemine (MSI-1436), a novel inhibitor of PTP-1B and Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity, during the 10th Biennial FASEB Summer Research Conference Protein Phosphatases in Snowmass Village, Colorado. The poster presentation entitled, "Trodusquemine (MSI-1436), An Allosteric Inhibitor of Protein Tyrosine Phosphatase 1B," concluded that MSI-1436 is a selective, reversible and noncompetitive inhibitor of PTP-1B that enhances insulin signaling through potent PTP-1B inhibition both in vivo and in vitro.

"The search to discover PTP-1B inhibitors as a therapeutic target for the treatment of obesity and type 2 diabetes has long been a goal of drug development but achieving the selectivity necessary to demonstrate safety has been a significant hurdle. The new information on the mechanism by which MSI-1436 inhibits PTP-1B supports its first-in-class status," stated Jack Armstrong, President and Chief Executive Officer of Genaera. "MSI-1436 is the only reversible, noncompetitive inhibitor of PTP-1B in clinical stage development. It is the allosteric nature of MSI-1436 and its ability to reversibly inhibit PTP-1B that is believed to be the key to the safety we have observed in Phase 1. We anticipate this will be attractive to both potential partners and clinicians as we obtain further evidence of the efficacy and safety of MSI-1436 in future studies."

Inhibition of PTP-1B, a non-receptor isoform of the protein tyrosine phosphatase family, by MSI-1436 has been shown to reduce food intake, induce weight loss, and increase insulin sensitivity
'/>"/>

SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
2. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
3. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
4. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
5. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
6. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
7. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
8. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
9. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
10. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
11. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... PLEASANTON, Calif. , July 30, 2015 ... it has submitted the cobas® EGFR Mutation Test ... Food and Drug Administration (FDA), as a companion ... for non-small cell lung cancer patients with an ... non-small cell lung cancer who have adenocarcinoma with ...
(Date:7/29/2015)... , July 29, 2015 Dignity Health ... Orthopedic Institute, combining the services of the hospital,s former ... one centralized location, and expanding services to include shoulder ... street from Saint Francis Memorial Hospital at 1199 Bush ... is a premier center aimed at providing a continuum ...
(Date:7/29/2015)... 2015  Unilife Corporation ("Unilife" or the "Company") (NASDAQ: ... and supplier of injectable drug delivery systems, today announced ... the Company with flexibility and control to support its ... an equity purchase agreement for up to $45 million ... Chicago -based institutional investor, which provides the ...
Breaking Medicine Technology:Roche submits filing to FDA for companion diagnostic for non-small cell lung cancer drug therapy 2Roche submits filing to FDA for companion diagnostic for non-small cell lung cancer drug therapy 3Saint Francis Memorial Hospital Orthopedic Institute Offers Comprehensive Orthopedic Care in One Location 2Unilife Announces Multifaceted Financing Strategy 2Unilife Announces Multifaceted Financing Strategy 3Unilife Announces Multifaceted Financing Strategy 4Unilife Announces Multifaceted Financing Strategy 5
... response to outbreaks of swine flu across North ... service, has issued professionally-written influenza notification scripts for ... protect the millions of families currently receiving One ... announced a NO-Charge, proactive emergency calling plan for ...
... two prospective, double-blind placebo controlled multi-center studies in patients ... and safety data in patients with focal dystonia and ... American Academy of Neurology,s (AAN) 61st annual meeting in ... which plans to file a Biologic License Application (BLA) ...
Cached Medicine Technology:One Call Now Offers Notification Service at NO CHARGE for Governments, Schools, Businesses, Religious Organizations and Others in Response to Swine Flu Outbreak 2One Call Now Offers Notification Service at NO CHARGE for Governments, Schools, Businesses, Religious Organizations and Others in Response to Swine Flu Outbreak 3Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients 2Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients 3Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients 4Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients 5
(Date:7/30/2015)... NY (PRWEB) , ... July 30, 2015 , ... ... and Sustamine® L-Alanyl-L-Glutamine for people on the go. With no water needed, the ... Chewable as a simple way to get the natural ingredients that may help ...
(Date:7/30/2015)... WASHINGTON (PRWEB) , ... July 30, 2015 , ... ... the scientific program at ATA’s 21st Annual Meeting and Tradeshow focused exclusively on ... more than 300 cutting-edge health care technology vendors, will take place May 14-17, ...
(Date:7/30/2015)... County, CA (PRWEB) , ... July 30, 2015 ... ... home health care throughout Orange, Riverside, Los Angeles, and San Bernardino counties, today ... as the new Palliative Care Administrator. Dr. Demoratz is a strong proponent of ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... and fourth annual Institute Scholar Program. In partnership with Patient Experience Institute, these ... experience, develop leaders on the front lines and throughout the experience movement, and ...
(Date:7/30/2015)... ... July 30, 2015 , ... The Mesothelioma Applied ... Mesothelioma Patient Registry Act of 2015’. The bill was introduced in Congress yesterday ... (R-NY), Betty McCollum (D-MN), Joe Kennedy (D-MA), and Leonard Lance (R-NJ). The purpose ...
Breaking Medicine News(10 mins):Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 2Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 3Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 3Health News:Bill to Create Patient Registry for Deadly Cancer Introduced in Congress 2
... In a case of dubious consolation, nineteen persons infected ... making this Chinas most moneyed lawsuit//. This money should ... as most of them are living in poverty. ... operations carried out at a provincial hospital of northern ...
... of Neurological disorders in their early stage or ... ,Melbourne researchers have found a relationship between ... roses and bleach and neurological disorders such as ... of the Melbourne Neuropsychiatry Clinic, Christos Pantelis said, ...
... Institute have found a protein that causes a brain wasting ... effects// the regulation of glucose in the blood stream. ... direct effect of the disease on the regulatory mechanism of ... in the blood is found as a twisted, deformed protein ...
... to multiple dogs along with presence of a certain ... says a new study//., ,David Bernstein, professor of ... found this after studying about 500 infants, reported online ... is associated with a higher risk of developing allergies ...
... that spanned over 3 decades was conducted by Danish ... risk of mental illnesses such as schizophrenia,// depression, or ... children were seldom seen admitted in psychiatric wards. Statistics ... risk than those who do not have children. ...
... started creating an online global map called as ‘Malaria Atlas ... the// areas where the disease is most likely to strike. ... supporting the project. ,It is reported that every ... per cent of the world's population is at risk of ...
Cached Medicine News:Health News:Detection of Neurological Disorder is Just a Sniff Away!! 2Health News:Juvenile Diabetes may Be Caused by Mad Cow Protein 2
Straight shafts with 1 x 2 teeth. Flat handle with haoles and polished finish. Delicate teeth. Most popular size or model....
Straight shafts with 0.12 mm teeth and 5 mm tying platform. Serrated handle with polished finish. Manufactured in titanium....
Straight shafts with polished finish. Teeth: 0.12 mm. Tying platform: 5.0 mm. Wide Serrated....
Straight shafts with 1 x 2 teeth and 5 mm tying platform. Serrated handle with dull finish....
Medicine Products: